Reactions to Rituximab in an Outpatient Infusion Center: A 5-Year Review

Journal of Allergy and Clinical Immunology: In Practice

Volumn 5, Issue 1, 2017, Pages 107-113.e1

  Levin, Amy S ^a   Otani, Iris M ^a   Lax, Timothy ^b   Hochberg, Ephraim ^b   Banerji, Aleena ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Desensitization; Infusion reaction; Monoclonal antibody; Rituximab

Indexed keywords

RITUXIMAB; ANTIASTHMATIC AGENT; IMMUNOGLOBULIN E;

ABDOMINAL PAIN; ADULT; ANGIONEUROTIC EDEMA; ARTICLE; BACKACHE; CHILL; COUGHING; DIAPHORESIS; DISEASE SEVERITY; DIZZINESS; DRUG EFFECT; DRUG EXPOSURE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FEMALE; FEVER; HOT FLUSH; HUMAN; HYPERTENSION; HYPOTENSION; INFUSION RELATED REACTION; MAJOR CLINICAL STUDY; MALE; NAUSEA; OUTPATIENT CARE; PRURITUS; RASH; RETROSPECTIVE STUDY; RIGOR; TACHYCARDIA; THORAX PAIN; THROAT DISEASE; THROAT ITCHINESS; THROAT TIGHTNESS; TREATMENT OUTCOME; URTICARIA; VOMITING; AGED; ANAPHYLAXIS; ASTHMA; DRUG HYPERSENSITIVITY; HOME INFUSION THERAPY; INCIDENCE; METABOLISM; MIDDLE AGED; OUTPATIENT DEPARTMENT; RISK; UNITED STATES;

AGED; AMBULATORY CARE FACILITIES; ANAPHYLAXIS; ANTI-ASTHMATIC AGENTS; ASTHMA; DRUG HYPERSENSITIVITY; EXANTHEMA; FEMALE; HOME INFUSION THERAPY; HUMANS; IMMUNOGLOBULIN E; INCIDENCE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK; RITUXIMAB; UNITED STATES;

EID: 84998996830     PISSN: 22132198     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaip.2016.06.022     Document Type: Article

References (20)

1. 1 Rituxan (rituximab) label. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/103705s5367s5388lbl.pdf. Accessed March 27, 2015.
2. 2 Oldham, R.K., Dillman, R.O., Monoclonal antibodies in cancer therapy: 25 years of progress. J Clin Oncol 26 (2008), 1774–1777.
3. 3 Onrust, S.V., Lamb, H.M., Barman Balfour, J., Rituximab. Drugs 58 (1999), 79–88.
4. 4 Maloney, D.G., Grillo-López, A.J., White, C.A., Bodkin, D., Schilder, R.J., Neidhart, J.A., et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90 (1997), 2188–2195.
5. 5 McLaughlin, P., Grillo-López, A.J., Link, B.K., Levy, R., Czuczman, M.S., Williams, M.E., et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16 (1998), 2825–2833.
6. 6 Byrd, J.C., Murphy, T., Howard, R.S., Lucas, M.S., Goodrich, A., Park, K., et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 19 (2001), 2153–2164.
7. 7 Castells, M.C., Tennant, N.M., Sloane, D.E., Ida Hsu, F., Barrett, N.A., Hong, D.I., et al. Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol 122 (2008), 574–580.
8. 8 Vultaggio, A., Matucci, A., Nencini, F., Pratesi, S., Petroni, G., Cammelli, D., et al. Drug-specific Th2 cells and IgE antibodies in a patient with anaphylaxis to rituximab. Int Arch Allergy Immunol 159 (2012), 321–326.
9. 9 Dillman, R., Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy. Cancer Metastasis Rev 18 (1999), 465–471.
10. 10 Herishanu, Y., Rituximab-induced serum sickness. Am J Hematol, 70, 2002, 329.
11. 11 Pichler, W.J., Adverse side-effects to biological agents. Allergy 61:8 (2006), 912–920.
12. 12 Lenz, H., Management and preparedness for infusion and hypersensitivity reactions. Oncologist 12 (2007), 601–609.
13. 13 National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. Available from: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf. Accessed April 12, 2015.
14. 14 Banerji, A., Lax, T., Guyer, A., Hurwitz, S., Camargo, C.A. Jr., Long, A.A., Management of hypersensitivity reactions to carboplatin and paclitaxel in an outpatient oncology infusion center: a 5-year review. J Allergy Clin Immunol Pract 2 (2014), 428–433.
15. 15 Brennan, P.J., Rodriguez Bouza, T., Hsu, F.I., Sloane, D.E., Castells, M.C., Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment. J Allergy Clin Immunol 124 (2009), 1259–1266.
16. 16 Abadoglu, O., Epozturk, K., Atayik, E., Kaptanoglu, E., Successful rapid rituximab desensitization for hypersensitivity reactions to monoclonal antibodies in a patient with rheumatoid arthritis: a remarkable option. J Investig Allergol Clin Immunol 21 (2011), 319–321.
17. 17 Sokol, C.L., Leung, J., Guyer, A.C., Long, A., Wong, J.T., Wilson, M.T., et al. Novel rituximab desensitization protocol increases safety of drug desensitization. J Allergy Clin Immunol, 129, 2012, AB371.
18. 18 Patil, S.U., Long, A.A., Ling, M., Wilson, M.T., Hesterberg, P., Wong, J.T., et al. A protocol for risk stratification of patients with carboplatin-induced hypersensitivity reactions. J Allergy Clin Immunol 129 (2012), 443–447.
19. 19 Winkler, U., Jensen, M., Manzke, O., Schulz, H., Diehl, V., Engert, A., Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood 94 (1999), 2217–2224.
20. 20 Castells, M.C., Anaphylaxis to chemotherapy and monoclonal antibodies. Immunol Allergy Clin North Am 35 (2015), 335–348.